1 week Ago By ABMN Staff
StockNews.com started coverage on shares of MediciNova ( NASDAQ:MNOV – Free Report ) in a report published on Thursday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.
Separately, D. Boral Capital assumed coverage on MediciNova in a research report on Monday, December 2nd. They set a “buy” rating and a $9.
00 target price for the company. Read Our Latest Analysis on MNOV MediciNova Price Performance Institutional Inflows and Outflows An institutional investor recently bought a new position in MediciNova stock. Jane Street Group LLC bought a new stake in MediciNova, Inc.
( NASDAQ:MNOV – Free Report ) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 14,138 shares of the biopharmaceutical company’s stock, valued at approximately $30,000. Institutional investors and hedge funds own 9.
90% of the company’s stock. About MediciNova ( Get Free Report ) MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
Read More Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter ..
